Table 1.
Demographic and clinical information of the entire patients
| Variables | All patients (n = 159) |
|---|---|
| Age (> 65/≤65 years), n (%) | 28/131 (17.6/82.4) |
| Sex (male/female), n (%) | 135/24 (84.9/15.1) |
| HBsAg (positive/negative), n (%) | 142/17 (89.3/10.7) |
| Albumin (> 35/≤35 g/dl), n (%) | 125/34 (78.6/21.4) |
| Total bilirubin (> 17.1/≤17.1 µmol/L), n (%) | 79/81 (49.1/50.9) |
| Prothrombin time (> 13/≤13 s), n (%) | 34/125 (21.4/78.6) |
| Creatinine (> 106/≤106 µmol/L), n (%) | 3/156 (1.9/98.1) |
| Blood glucose (> 7/≤7 mmol/L), n (%) | 25/134 (15.7/84.3) |
| Platelet (> 100/≤100 10^9/L), n (%) | 133/26 (83.6/16.4) |
| ALBI grade (1/2/3), n (%) | 87/71/1 (54.7/44.7/0.6) |
| Alpha fetoprotein (≥ 400/<400 ng/mL), n (%) | 74/85 (46.5/53.5) |
| PIVKA-II (≥ 2050/<2050 mAU/mL), n (%) | 68/91 (42.8/57.2) |
| Liver cirrhosis (yes/no), n (%) | 118/41 (74.2/25.8) |
| Tumor nodules (single/multiple), n (%) | 35/124 (22/78) |
| Maximal tumor diameter (≤ 5/>5 cm), n (%) | 30/129 (18.9/81.1) |
| Extrahepatic metastases (yes/no), n (%) | 27/132 (17.0/83.0) |
| Portal vein tumor thrombus (with/without), n (%) | 47/102 (29.6/70.4) |
| BCLC stage (B/C), n (%) | 100/59 (62.9/37.1) |
| Tumor response (CR/PR/SD/PD), n (%) | 6/46/25/82 (3.8/28.9/15.7/51.6) |
Abbreviations: HBsAg Hepatitis B surface antigen, ALBI, Albumin-bilirubin, PIVKA-II Protein induced by vitamin K absence or antagonist-II, BCLC Barcelona Clinic Liver Cancer, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease